• Eli Lilly and Co., of Indianapolis, reported new data showing that Forteo significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis. Read More
• Perrigo Co., of Allegan, Mich., filed an abbreviated new drug application with the FDA for a generic version of Axiron (testosterone) topical solution, originally developed by Acrux Ltd., of Melbourne, Australia, and Eli Lilly and Co., of Indianapolis. Read More
• Genervon Biopharmaceuticals LLC, of Pasadena, Calif., said it received FDA approval for an amyotrophic lateral sclerosis (ALS) Phase IIa trial for GM604, which has been found to modulate more than 80 ALS-related gene targets (efficacy and target biomarkers) interactively and dynamically, through up to 12 pathways and 22 biological processes. Patient recruitment for the trial has started. Read More
• Cardiome Pharma Corp., of Vancouver, British Columbia, said its board adopted an advance notice policy regarding the nomination of directors, establishing a deadline and written process by which registered or beneficial holders of the company's common shares (NASDAQ:CRME) must submit nominations to the company prior to an annual or special shareholder meeting. Read More
• NPS Pharmaceuticals Inc., of Bedminster, N.J., closed a public offering of 6.9 million shares of common stock at $14.53 per share; 900,000 of the shares were sold pursuant to the underwriters' exercise of an overallotment option. Read More
Several decades ago, scientists recognized that triggering the series of biochemical events that lead to changes in cell morphology, and ultimately cell death, could be applied in a therapeutic fashion, along with the clearance of apoptotic cells, which is essential to regulate inflammation and maintain immunotolerance. Read More
A peptide based on sea anemone venom, already in early clinical trials for autoimmune diseases, also shows promise in the metabolic arena, scientists reported this week. Read More
While partnering strategies can provide access to essential products and technology, mergers and acquisitions can achieve the same goals and also provide greater leverage and control of the acquired assets. Read More
